OUR MISSION
Tackling parasitic, bacterial, helminthic & viral infections of the developing world
|
The McNamara Lab is located at Calibr-Skaggs Institute for Innovative Medicines, a translation drug discovery division of The Scripps Research Institute. My research team is primarily focused on the discovery and development of antimalarials for the prevention and treatment of malaria, antibiotics that will permit treatment shortening for tuberculosis and novel therapies to treat and control schistosomiasis.
I co-lead the extended infectious disease team with Malina Bakowski. Her team is dedicated to Chagas disease, Influenza, and antimicrobial resistance (AMR). Our goal, as a drug discovery unit, is to establish the necessary in vitro and in vivo workflow that will fully enable the preclinical development of novel drugs. This entails the development of miniaturized phenotypic assays in 384- or 1536-well format for high-throughput screening, designing orthogonal assays to characterize novelty and prioritization of hit compounds, and target identification. |
Calibr-Skaggs
Institute for Innovative Medicines
|
DRUG DISCOVERY PLATFORMS
Small molecules Biologics: engineered peptides and antibodies Cell-based therapies |
DISEASE AREAS
Oncolytic Metabolic Regenerative Medicine Infectious Disease |
A Team EnvironmentOur biology teams are supported with experienced drug discovery personnel throughout the institute and an impressive infrastructure.
The High-Throughput Screening group supports automated screening and data processing, the Compound Management Group oversees organization and quality assurance for the thousands of compounds synthesized by the Medicinal Chemistry groups and Calibr's 800,000 compound screening library, and, finally, the Pharmacology team supports in vivo profiling. |
BIRD'S-EYE VIEW OF uHTS SYSTEM IN ACTION (sound on)
|
